ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong · Delayed Price · Currency is HKD 5.94
-0.17 (-2.78%)
Apr 17, 2026, 4:08 PM HKT
HKG:1541 Revenue
In the year 2025, ImmuneOnco Biopharmaceuticals (Shanghai) had annual revenue of 154.29M CNY with 93.99% growth. ImmuneOnco Biopharmaceuticals (Shanghai) had revenue of 110.28M in the half year ending December 31, 2025, with 1,578.28% growth.
Revenue
154.29M CNY
Revenue Growth
+93.99%
P/S Ratio
15.36
Revenue / Employee
763.83K CNY
Employees
202
Market Cap
2.64B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 154.29M | 74.76M | 93.99% |
| Dec 31, 2024 | 79.54M | 71.84M | 933.61% |
| Dec 31, 2023 | 7.70M | 2.01M | 35.24% |
| Dec 31, 2022 | 5.69M | -8.12M | -58.79% |
| Dec 31, 2021 | 13.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 2.00B |
| AIM Vaccine | 1.30B |
| BioDlink International Company | 831.99M |
| Mabpharm | 718.98M |
| Medtide | 634.40M |
| Mirxes Holding Company | 166.32M |
| Jiangsu Recbio Technology | 14.16M |
| SinoMab BioScience | 6.28M |